Literature DB >> 14526684

Anaplastic large cell lymphoma presenting as a pleural effusion and mimicking primary effusion lymphoma. A report of 2 cases.

Alexander Chak-Lam Chan1, John Kwok-Cheung Chan, Kin Wing Yan, Yok Lam Kwong.   

Abstract

BACKGROUND: Systemic anaplastic large cell lymphoma (ALCL) is predominantly a nodal disease, but extranodal involvement can occur during the disease course or as the primary presentation. We report two rare cases of ALCL presenting with a pleural effusion, mimicking primary effusion lymphoma (PEL). CASES: Two patients, a 47-year-old woman and an 81-year-old man, presented with a pleural effusion for investigation. The pleural fluid contained abundant, large, lymphoid cells with marked nuclear atypia. These neoplastic cells strongly expressed CD30 and EMA and showed a T-cell phenotype (CD3+CD45RO+ for case 1 and CD4+ for case 2). Case 1, in addition, showed ALK1 expression. The tumor cells in both cases were negative for human herpes virus type 8 (HHV8) and Epstein-Barr virus (EBV). ALCL shows overlapping cytologic features with PEL, but the T-cell phenotype, ALK1 expression in case 1, lack of association with HHV8 and EBV, HIV seronegativity and subsequent discovery of nodal disease in case 2 were all in favor of ALCL over PEL.
CONCLUSION: In rare cases a pleural effusion is the presenting feature of ALCL, and distinction from PEL depends on correlation with clinical findings, detailed immunophenotyping and study of the status of HHV8 and EBV.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14526684     DOI: 10.1159/000326611

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  8 in total

Review 1.  Current status of treatment for primary effusion lymphoma.

Authors:  Seiji Okada; Hiroki Goto; Mihoko Yotsumoto
Journal:  Intractable Rare Dis Res       Date:  2014-08

2.  An unusual case of posttransplant peritoneal primary effusion lymphoma with T-cell phenotype in a HIV-negative female, not associated with HHV-8.

Authors:  Ioannis Venizelos; Demetrio Tamiolakis; Maria Lambropoulou; Sylva Nikolaidou; Sophia Bolioti; Hlias Papadopoulos; Nikolas Papadopoulos
Journal:  Pathol Oncol Res       Date:  2005-09-29       Impact factor: 3.201

3.  Primary effusion anaplastic large cell lymphoma with indolent clinical course and IRF4/DUSP22 rearrangement: a case report expanding the spectrum of effusion-based lymphoma.

Authors:  Chang-Tsu Yuan; Ann-Lii Cheng; Hsin-An Hou
Journal:  Virchows Arch       Date:  2022-08-19       Impact factor: 4.535

Review 4.  Pleural effusion as a rare sign of anaplastic large-cell lymphoma in a COVID-19 patient: A case report and literature review.

Authors:  Omar Kamel; Laurence Rozen; Sophie Lecomte; Pierre Heimann; Anne Demulder
Journal:  Int J Lab Hematol       Date:  2021-03-24       Impact factor: 3.450

5.  Human Immunodeficiency Virus (HIV)-Negative and Human Herpes Virus-8 (HHV-8)-Positive Primary Effusion Lymphoma: A Case Report and Review of the Literature.

Authors:  Sonay Güven Karataş; Reyhan Bayrak; Ozlem Sahin Balçık; Kadir Serkan Yalçın; Esra Atıcı; Umit Akyıldız; Ali Koşar
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

Review 6.  Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment.

Authors:  Xin-Rui Zhang; Pham-Ngoc Chien; Sun-Young Nam; Chan-Yeong Heo
Journal:  Cancers (Basel)       Date:  2022-03-24       Impact factor: 6.639

7.  HHV8-Negative Primary Effusion Lymphoma of B-Cell Lineage: Two Cases and a Comprehensive Review of the Literature.

Authors:  Neeraj Saini; Ephraim P Hochberg; Erica A Linden; Smita Jha; Heinz K Grohs; Aliyah R Sohani
Journal:  Case Rep Oncol Med       Date:  2013-01-16

8.  An unusual case of Primary Effusion Lymphoma with aberrant T-cell phenotype in a HIV-negative, HBV-positive, cirrhotic patient, and review of the literature.

Authors:  Charitini Nepka; Dimitrios Kanakis; Maria Samara; Andreas Kapsoritakis; Spyridon Potamianos; Maria Karantana; Georgios Koukoulis
Journal:  Cytojournal       Date:  2012-06-29       Impact factor: 2.091

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.